Papers to Appear in Forthcoming Issues

Breakdown of Th Cell Immune Responses and Steroidogenic CYP11A1 Expression in CD4+ T Cells in a Murine Model Implanted with B16 Melanoma. Hideki Oka, Yoshiro Hayashi, Yutaka Emori, and Kikuo Nomoto. (Received 5/30/00; accepted 9/15/00.) fication of a ras Oncogene Peptide That Contains Both CD4+ and CD8+ T Cell Epitopes in a Nested Configuration and Elicits Both T Cell Subset Responses by Peptide or DNA Immunization. J. Andrew Bristol, Caroline Orsini, Peter Lindinger, Josef Thalhamer, and Scott I. Abrams. (Received 6/16/00; accepted 9/15/00.) s of Raloxifene, a Selective Estrogen Receptor Modulator, on Thymus, T Cell Reactivity, and Inflammation in Mice. M. C. Erlandsson, E. Gömöri, M. Taube, and H. Carlsten. (Received 6/30/00; accepted 9/25/00.) al (Cord Blood) T Cells Can Competently Raise Type 1 and 2 Immune Responses upon Polyclonal Activation. James Chipeta, Yoshihiro Komada, Xao-Li Zhang, Eiichi Azuma, Hatsumi Yamamoto, and Minoru Sakurai. (Received 7/1/00; accepted 9/19/00.) ne Up-Regulates Expression of Substance P and Its Receptor in Human Blood Mononuclear Phagocytes and Lymphocytes. Yuan Li, Sha Tian, Steven D. Douglas, and Wen-Zhe Ho. (Received 7/7/00; accepted 9/15/00.) in Induces IL-6 but Not TNFα Secretion by Mouse Mast Cells: Threshold-Level Thrombin Receptor and Very Low Level FcϵRI Signaling Synergistically Enhance IL-6 Secretion. John R. Gordon, Xiaobei Zhang, and Kevin Cosford. (Received 7/11/00; accepted 9/15/00.)